SynBioBeta 2027 Super Early Bird pricing is available through Friday, June 15.
Join the AIxBio founders, biopharma leaders, investors, and startups building the future of biology.
Presenting sponsor: Pumpkinseed
May 3–6, 2027 | San Jose, CA
Lock in your pass early.
syntheticbiologysummit.com/2…
Incredible data from Armon Sharei at @portal_biotech this week.
@AnthropicAI's Claude designed siRNA that knocked down two different genes. @OpenAI's GPT-5 and @GoogleDeepMind's Gemini designed sequences that did nothing.
Armon used the same one line prompt across all three models: "Please give me your top 3 siRNA sequences for knocking down [gene] in human peripheral blood mononuclear cells."
siRNA is small interfering RNA. A short piece of RNA that finds the matching mRNA inside a cell and destroys it. The gene stays intact, the message never becomes a protein. The hard part is picking a sequence that hits the right transcript and nothing else.
The two targets were B2M and CD45. Both well known, both already carrying real clinical programs.
B2M, beta-2 microglobulin. The shared subunit of every MHC class I molecule.
- @CRISPRTX zugocaptagene geleucel, formerly CTX112. CD19 allogeneic CAR T, B2M knocked out for immune evasion
- @SanaBiotech SC291. CD19 allogeneic CAR T on their hypoimmune platform: B2M and CIITA out, CD47 in
CD45, also called PTPRC. The pan-leukocyte phosphatase, on every white blood cell and almost nothing else.
- @ActiniumPharma Iomab-B, an iodine-131 anti-CD45 antibody, Phase 3 in AML
One is a target for making allogeneic T cells. The other is a target for clearing a patient's own blood cells out of the marrow so that a donor stem cell graft has room to engraft.
The results, with all sequences delivered straight into the cytosol of primary human PBMCs on Portal's Gateway and read out at day 3:
B2M, non-targeting control 7.5%
- Claude: 74.7%
- GPT-5: 26.8%
- Gemini: 5.5%
CD45, non-targeting control 0.7%
- Claude: 97.9%
- GPT-5: 2.8%
- Gemini: 5.6%
The type of design thinking necessary to come up with an siRNA construct used to take specialized skills and know-how.
Today, in one prompt, we have access to 0-shot siRNA design.
Nowhere on Earth produces more almonds than California.
The state supplies nearly 80% of the world's almonds. That's enough to fill 50,000 semi-trucks, bumper to bumper.
But almonds weren't always a California success story.
In the late 1700s, Spanish missionaries brought almonds to Mexico, then north into Alta California.
Along the coast, they built 21 missions, stretching from San Diego to Sonoma.
One of the most ambitious was Mission San Gabriel Arcángel, founded in 1771 near what's now Los Angeles. The missionaries planted citrus, olives, grapes, and almonds.
But the almond trees, likely early Spanish types like Desmayo Largueta, struggled.
The coastal humidity slowed their growth, and the harvests were sparse.
Meanwhile, other crops flourished.
Grapes became wine. Olives yielded oil. Citrus took over the inland valleys.
These Mediterranean staples helped shape California's early farming identity.
Almonds quietly vanished from the landscape.
For nearly a century, they were forgotten, until new settlers from the east arrived, bringing different crops, new methods, and a hunger for what California soil could offer.
Among them was a curious entrepreneur named Arthur T. Hatch.
Like many Californians at the time, he dabbled in mining, trade, and postal work before landing on farming.
On a hundred acres of land near Vacaville, he planted dozens of fruit and nut trees side by side, testing which could handle the region's heat and drought.
He watched which trees bloomed early, which nuts cracked cleanly, and, most importantly, which came back strong year after year.
One almond variety kept outperforming the rest.
Its kernels were large, sweet, and easy to shell. They required less labor and fetched higher prices when brought to the local market.
Hatch named it Nonpareil: "without equal."
In 1883, Hatch brought his products to the Vacaville Citrus Fair, a gathering that drew growers, nursery operators, and buyers from across California.
Most came expecting to see citrus, stone fruit, and grapes. Almonds were an outlier. Few believed they could be commercially grown here at all.
But Hatch's trees told a different story.
They had survived the Central Valley's climate. They had produced consistent, high-quality nuts. And now, they were on display for everyone to see.
The effect rippled.
Growers from other valleys saw the potential. Nurseries began requesting cuttings.
And for the first time, almonds were seen as a potential crop.
In a single season, Nonpareil went from curiosity to cornerstone.
Today, California almonds are everywhere.
Pressed into milk. Blended into protein bars. Ground into flour.
The edible kernel alone powers a multi-billion dollar global market.
But that's only part of the story.
Because the kernel, the part we eat, makes up just one-third of the almond by weight.
The other two-thirds?
They don't end up on your plate.
They're put to work in ways few consumers ever see.
The best cancer targets may be hiding in how genes are spliced, not in the genes themselves.
"One of the biggest bottlenecks is no longer just how to build the drug, it's where to point it."
@envisagenics x @Boehringer Ingelheim. Deals like this start in the room.
Visit the SynBioBeta website to read the full article.
synbiobeta.com/read/the-drug…
Subscribe to our newsletter and get the biggest biotech news straight to your inbox 🧬
syntheticbiologysummit.com/?…
🔥 Week 47! 37 Bay Area Bio-economy events, Nov 16–22 🔥
David Baker gives two C. H. Li Memorial Lectures at @UCBerkeley. Randy Schekman with MCBcDNA. @GladstoneInst awards the Ogawa-Yamanaka Stem Cell Prize to Jun Takahashi. @biohub, @AnthropicAI and @nvidia on ESMFold2. All free.
🔗docs.google.com/spreadsheets… 🔗
The sheet has two tabs.
📅 By Day runs in calendar order, so you can plan your week.
🗂️ By Topic groups every event by field, so you can jump straight to yours.
𝗕𝗬 𝗧𝗢𝗣𝗜𝗖
🧬 9: Genomics, Proteins & Omics
🤖 7: AI & Computation
🌱 6: Industrial & Environmental Bio
🔬 4: Tools, Automation & Lab Ops
🧠 4: Neuro & BCI
💊 2: Drug Discovery & Trials
🏥 2: Clinical & Care Delivery
💰 2: Capital & Dealmaking
🎓 1: Career & Training
𝗕𝗬 𝗙𝗢𝗥𝗠𝗔𝗧
21: Seminar & Talk
11: Webinar
3: Conference & Summit
2: Networking & Social
𝗕𝗬 𝗟𝗢𝗖𝗔𝗧𝗜𝗢𝗡
13: Virtual
9: Berkeley
8: San Francisco
4: Stanford
2: South San Francisco
1: San Carlos
𝗕𝗬 𝗗𝗔𝗬
5: Monday, Nov 16
7: Tuesday, Nov 17
7: Wednesday, Nov 18
12: Thursday, Nov 19
5: Friday, Nov 20
1: Saturday, Nov 21
Thanks to the hosts: MBC BioLabs Berkeley Gateway Accelerator @GladstoneInst@biohub@OpenAI@LaunchBio@elucidatacorp@PythiaBio Rellia Health @BakerInstitute@RiceUniversity MCBcDNA @frontiertower@NeuroTechX@CALifeSciences@QBI_UCSF@genentech@teqfocus
I had the privilege of interviewing @BrianTHeligman, CEO and co-founder of @biosphereio, after their recent $21M award from the United States @DeptofWar.
It's been great to see so much government interest in more efficient formats of biomanufacturing. This one cleans a tank with light instead of steam.
Biosphere is building a 20,000-liter fermenter in the Bay Area. It has to stay nearly as clean as a drug plant. It will be sterilized with UV, not steam.
Why that matters:
- Steam sterilization turns the tank into a pressure cooker. That means thick, pressure-rated steel, a boiler, and a web of pipes and valves designed to drain clean.
- The tank itself isn't the most expensive part. The piping, utilities, and cleaning systems around it can cost several times as much as the vessel.
- UV works on smooth, hard surfaces, and the inside of a tank is mostly smooth, hard surfaces. With no steam, there's no pressure rating to meet. That means less steel and far less plumbing.
- Pharma got around steam with single-use bags. But bags top out at a few thousand liters, and the disposable parts can run tens of thousands of dollars per batch. That works for drugs. It doesn't work for chemicals or food.
Enzymes, food ingredients, and specialty chemicals need near-pharma cleanliness at chemical-industry prices. That gap has stalled a lot of companies whose science already works.
Why the Department of War is paying for it:
- Many chemicals the military needs have little civilian demand, and defense spending on them goes up and down. Traditional manufacturers won't build U.S. capacity on that.
- The department isn't buying chemicals yet. It's buying proof that a cheaper plant design works at a scale that matters, plus the engineering and economic analysis to judge bigger ones.
- 20,000 liters is 20x the 1,000-liter systems military labs use for test batches. Most commercial fermentation tanks are no more than about 10x bigger.
As Brian put it: "you need demonstration of robustness at a relevant scale to be taken seriously."
This is Biosphere's second defense award this year. It's part of a broader pattern too. @CapraBio, @antheiabio, and @CaCultured are all rethinking how and where things get made, often with government money behind them.
Steel-and-steam plants cost too much for most new products, so companies are redesigning the hardware itself.
You can read more about this on the @SynBioBeta website, link in the comments.
Huge congratulations to @Amyris and @ooblifoods.
Oobli's co-founder used to work at Amyris. Today Amyris announced it's acquiring his company. Both have been part of the SynBioBeta community for years.
Jason Ryder co-founded Oobli in 2014 as Joywell Foods. Before that he held senior technical roles at Amyris, Bolt Threads, and Hampton Creek. Chemical engineer, Berkeley PhD, a career spent scaling molecules and proteins. Twelve years later, the sweet protein company he started is joining the company where he once worked.
The origin story is a good one. A Joywell founder was looking for ways to help his grandmother enjoy food again after chemotherapy damaged her sense of taste. That search led to sweet proteins: molecules found in rare fruits and berries near the equator that taste like sugar but digest as protein.
What Oobli built from there:
- Went through @indbio SF in 2016
- Brought in Ali Wing as CEO and rebranded from Joywell to Oobli in late 2022
- Became the first company to receive FDA "no questions" GRAS letters for novel sweet proteins (brazzein and monellin)
- Raised nearly $60M from @khoslaventures, Piva Capital, B37 Ventures, Ingredion Ventures and others
- Signed partnerships with Grupo Bimbo and @Ingredion
Oobli at SynBioBeta:
- 2023: Jason joined our alternative proteins panel and brought an Igloo cooler of Oobli iced tea on stage
- 2024: Ali spoke on our scale-up panel about lessons from biomanufacturing failures and successes
- 2026: Jason and COO Nick Ohler were both back as speakers
Amyris goes back even further with us. They first spoke at SynBioBeta in 2013. John Melo, Kirsten Benjamin, Joel Cherry, Darren Platt and Sunil Chandran have all taken our stages over the years, on everything from strain throughput to synbio beauty.
The company has changed a lot since then. Kathy Fortmann took over as CEO in May 2024 and rebuilt Amyris after bankruptcy around B2B precision fermentation. In March they brought a fourth production line online in Barra Bonita, Brazil. Now they're adding a protein platform with regulatory approvals and brand partners already in place.
There's a nice through line here too. Amyris built the fermented Reb M stevia technology that Ingredion now commercializes. Ingredion is also an Oobli investor and partner, pairing sweet proteins with stevia.
Two things I take from this:
- Strain engineering and manufacturing scale are worth the most when paired with a product that already has approvals and customers
- Synbio people circulate. The alumni of the last wave are building the companies the next wave acquires
Sunil returns for SynBioBeta 2027 on our BioSolutions track.
I hope the combined team has a lot to share.
Kathy, Ali, Jason, and both teams: congratulations.
Huge congratulations to @Amyris and @ooblifoods.
Oobli's co-founder used to work at Amyris. Today Amyris announced it's acquiring his company. Both have been part of the SynBioBeta community for years.
Jason Ryder co-founded Oobli in 2014 as Joywell Foods. Before that he held senior technical roles at Amyris, Bolt Threads, and Hampton Creek. Chemical engineer, Berkeley PhD, a career spent scaling molecules and proteins. Twelve years later, the sweet protein company he started is joining the company where he once worked.
The origin story is a good one. A Joywell founder was looking for ways to help his grandmother enjoy food again after chemotherapy damaged her sense of taste. That search led to sweet proteins: molecules found in rare fruits and berries near the equator that taste like sugar but digest as protein.
What Oobli built from there:
- Went through @indbio SF in 2016
- Brought in Ali Wing as CEO and rebranded from Joywell to Oobli in late 2022
- Became the first company to receive FDA "no questions" GRAS letters for novel sweet proteins (brazzein and monellin)
- Raised nearly $60M from @khoslaventures, Piva Capital, B37 Ventures, Ingredion Ventures and others
- Signed partnerships with Grupo Bimbo and @Ingredion
Oobli at SynBioBeta:
- 2023: Jason joined our alternative proteins panel and brought an Igloo cooler of Oobli iced tea on stage
- 2024: Ali spoke on our scale-up panel about lessons from biomanufacturing failures and successes
- 2026: Jason and COO Nick Ohler were both back as speakers
Amyris goes back even further with us. They first spoke at SynBioBeta in 2013. John Melo, Kirsten Benjamin, Joel Cherry, Darren Platt and Sunil Chandran have all taken our stages over the years, on everything from strain throughput to synbio beauty.
The company has changed a lot since then. Kathy Fortmann took over as CEO in May 2024 and rebuilt Amyris after bankruptcy around B2B precision fermentation. In March they brought a fourth production line online in Barra Bonita, Brazil. Now they're adding a protein platform with regulatory approvals and brand partners already in place.
There's a nice through line here too. Amyris built the fermented Reb M stevia technology that Ingredion now commercializes. Ingredion is also an Oobli investor and partner, pairing sweet proteins with stevia.
Two things I take from this:
- Strain engineering and manufacturing scale are worth the most when paired with a product that already has approvals and customers
- Synbio people circulate. The alumni of the last wave are building the companies the next wave acquires
Sunil returns for SynBioBeta 2027 on our BioSolutions track.
I hope the combined team has a lot to share.
Kathy, Ali, Jason, and both teams: congratulations.
Last year, @bitsinbio broke the news on @AnthropicAI and their rapid gain in the life sceinces. Claude use among TechBio builders nearly doubled in a year, from 32% to 60%, pulling almost even with @OpenAI at 62%.
Since 2022, Bits in Bio has been one of the leading sources of longitudinal data on AI and tool adoption across the life sciences and we need your help to continue that trend.
We're back for a fifth consecutive year of tracking these trends. We'd be incredibly grateful if you could spend 5 to 10 minutes to help us stay a source of signal in a field full of noise:
form.typeform.com/to/hXVnAtp…
"It's a really challenging time to invest in synthetic biology because of AI. By the time you finish diligence, the field has moved."
- Noga Golan of Food Impact Partners. #SynBioBeta2027syntheticbiolgoysummit.com/?…
Three interesting numbers about China's CRO industry:
• Customers: 72% of WuXi AppTec's continuing revenue (~31B RMB) comes from the US. It has ~6,000 active customers, with the top 20 pharma companies accounting for 42% of revenue. The other 58% comes from the long tail.
• Capacity: China has an estimated 35–45k in-vitro discovery scientists in CROs vs. 2.5–3.5k in the US. Revenue per employee is similar (~$190k vs. $204k), but employee costs are ~$44k vs. ~$100k.
• Economics: An estimated 10–30% of a $50–100M small-molecule Series A goes to Chinese CROs.
US biotech isn't simply outsourcing to save money. It's relying on Chinese CRO infrastructure to make its R&D economics work.
jimmy @jimmy_build2026 Nov 7 Article Who is actually buying Chinese CROs, and when your own lab beats them This is first-hand work. Over the past months I visited labs and CRO sites in person, talked to the people running them, and compiled the numbers myself from annual reports, prospectuses and my own
Deep in the recesses of @ucsf, for five years and $67 million, @GSK funded some of the hardest CRISPR experiments ever run.
In 2025, Alexander Brown took the helm of the operation and this week, he opened the doors to everyone else as their work with GSK winds down.
The Laboratory for Genomics Research was founded in 2019 by Jennifer Doudna with Jonathan Weissman and Hal Barron, a hybrid lab across @UCBerkeley, @UCSF and GSK built for functional genomics at a scale no lab could reach.
Alex took over in August 2025. He came from industry, doing some of the hardest to engineer CRISPR programs money could pay for: four and a half years at @Synthego building and maintaining its Cell Engineering Services, then leading development at EditCo Bio when that function spun out. At EditCo he brought the first genome-edited human T cells to market.
This week he and his team, Gil Sharon (also ex-Synthego) and Sailaja Peddada, laid out what the LGR will now run for outside groups.
SCREENS
Genome-scale and targeted. Pooled and arrayed. Knockout, interference and activation.
LIBRARIES
Custom pooled and arrayed design and construction. Single and dual guide. Plasmid, glycerol or lentiviral. Built for high uniformity and low skew.
AUTOMATION
BSL-2 automated workcells. High-throughput liquid handling. Automated colony picking. Parallel processing built for scale.
READOUTS
Single-cell genomics and Perturb-seq. Arrayed high-content imaging. Flow and FACS. Multiparametric phenotyping.
DATA SCIENCE
Screen analysis and hit prioritization. Bulk and single-cell analysis. Image analysis. Biological interpretation.
MODELS
Immortalized lines, primary cells, iPSC-derived models and 3D organoids.
What that infrastructure produces: Viviana Salinas-Rios is building over a thousand bespoke editors at the Innovative Genomics Institute to find the most precise one for individual patient variants from the clinic.
Daniel Fletcher ran a genome-wide screen on cell surface crowding, where crowding costs an antibody 10 to 100 fold in binding affinity, and found no master regulator, just dozens of genes nudging it.
Also presenting: James Nuñez, Michael McManus, Roberto Zoncu, Han Yang, Anna Molofsky, Martin Kampmann, Zev Gartner, Alanna Schepartz.
@DoudnaJennifer closed the day with @genophoria of @arcinstitute and David Raleigh,
with a quote:
"(The) kind of data you're all generating is incredibly important. It's high quality data, which we all know doesn't always exist."
If you have a screen you cannot run yourself, whether you are in academia, a startup, or a Fortune 500 pharma, they are reachable at:
genomicsresearch@ucsf.edu
Thanks to @illumina , @thermofisher and @wilsonsonsini for sponsoring such a wonderful event.
Founders raising for frontier science, researchers ready to leave the lab, and investors ready to back them: meet each other at our Founder & Funder Mixer on Sunday, Nov 15, in Berkeley.
For people building and funding at the frontier of science and technology, with curated intros across:
• Secure and sovereign AI
• Molecular manufacturing and nanotech
• Neurotech and neuro AI
• Space and energy
• Longevity biotech
Applications are reviewed on a rolling basis, and researchers can request a subsidized ticket: luma.com/foresight-vq9z
Powered by: @protocollabs Capital, @Convergent_FROs, @frachtisvc, and @RenPhilanthropy.
Community partners: @JoinEdgeCity, @LBF_org, @SynBioBeta, and @theresidency.
@Mojikarimi from @Cemvita is in town next week for and wanted @bitsinbio to curate a group of local SF individuals working in industrial biology to talk about their work.
Friday, Nov 13, 3pm PST in SF.
🔗luma.com/dotwef73
Cemvita has one of the more interesting arcs in industrial biotech.
Moji and his sister @TaraScience founded it in Houston in 2017 with a solution before a problem: if you could replicate photosynthesis and turn CO2 into sugar, what could you fix? The answer turned out to be heavy industry. Oil and gas, mining, chemicals. Customers nobody in biotech was selling to. Occidental, @bhp, Mitsubishi Corporation, and @united all invested.
Then it became a startup of startups:
- @GoldHydrogen spun out to use microbes in depleted oil wells to make hydrogen, after a successful Permian Basin pilot, with @ChartInd and 8090 Industries as founding investors
- Endolith spun out to do biomining for copper and lithium, now led by Cemvita's former CTO Liz Dennett and working with BHP
- The core business moved to turning waste into oil, scaling its FermOil process to a 75,000-liter run at @BioBaseEuropePP
Now the focus has shifted again. Cemvita is building VITA, a platform that connects BioSolutions discovery, development, and deployment for energy, mining, water, and materials. Last month it launched the vision with @GreentownLabs in Houston and named @roeblingapp its AI-native engineering partner. The bet: use nearly a decade of real industrial data to kill bad projects on paper before anyone builds a plant.
Moji's own story fits the company. He's a drilling and petroleum engineer, not a biologist, who started out at @WeatherfordCorp. Before Cemvita he joined Biota Technology when it was three people, opened its Houston office, and grew DNA sequencing for the energy industry into a multimillion-dollar business in two years.
He's coming straight from @decodingbio in Boston to @ForesightInst's Vision Weekend, Nov 13-15 across the Bay Area, which this year celebrates 40 years of Foresight backing frontier science and technology. He'll share what he's hearing on the road. Then it's an open conversation.
🔗luma.com/dotwef73#IndustrialBiotechnology#BioSolutions#AI#Biomanufacturing
13 million bottles sold, every one transparently labelled GMO. Zack Abbott of @ZBioticsCompany on why consumer resistance to engineering was never really about the engineering. #SynBioBeta